$44.98
-0.13[-0.29%]
At close: Apr 24
$44.98
0[0.00%]
After Hours: 4:36PM EDT
Ultragenyx Pharmaceutical reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Ultragenyx Pharmaceutical using advanced sorting and filters.
Date | time | ticker | Quarter | Prior EPS | Est EPS | Actual EPS | EPS Surprise | Prior Rev | Est Rev | Actual Rev | Rev Surprise | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|---|
05/06/2024 | PM | RARE | Q1 | -$2.33 | -$1.76 | — | — | $100.50M | $116.17M | — | — | Get Alert |
02/15/2024 | PM | RARE | Q4 | -$2.16 | -$1.62 | -$1.52 | 6.17% | $103.35M | $119.38M | $127.39M | 6.71% | Get Alert |
11/02/2023 | PM | RARE | Q3 | -$2.43 | -$2.06 | -$2.23 | -8.25% | $90.70M | $110.02M | $98.05M | -10.88% | Get Alert |
08/03/2023 | PM | RARE | Q2 | -$2.26 | -$2.11 | -$2.25 | -6.64% | $89.34M | $105.20M | $108.31M | 2.96% | Get Alert |
05/04/2023 | PM | RARE | Q1 | -$2.19 | -$1.98 | -$2.33 | -17.68% | $79.94M | $104.69M | $100.50M | -4.01% | Get Alert |
02/16/2023 | PM | RARE | Q4 | -$1.79 | -$2.14 | -$2.16 | -0.93% | $83.39M | $105.12M | $103.35M | -1.69% | Get Alert |
11/02/2022 | PM | RARE | Q3 | -$1.08 | -$1.81 | -$2.43 | -34.25% | $81.65M | $96.20M | $90.70M | -5.71% | Get Alert |
07/28/2022 | PM | RARE | Q2 | -$1.81 | -$1.75 | -$2.26 | -29.14% | $86.97M | $87.51M | $89.34M | 2.09% | Get Alert |
05/05/2022 | PM | RARE | Q1 | -$2.03 | -$1.76 | -$2.19 | -24.43% | $99.39M | $83.65M | $79.94M | -4.44% | Get Alert |
02/10/2022 | PM | RARE | Q4 | -$0.37 | -$1.34 | -$1.79 | -33.58% | $91.54M | $83.79M | $83.39M | -0.48% | Get Alert |
11/02/2021 | PM | RARE | Q3 | -$1.13 | -$1.41 | -$1.08 | 23.40% | $81.47M | $81.55M | $81.65M | 0.12% | Get Alert |
08/02/2021 | PM | RARE | Q2 | -$1.12 | -$1.36 | -$1.81 | -33.09% | $61.71M | $85.03M | $86.97M | 2.29% | Get Alert |
05/04/2021 | PM | RARE | Q1 | -$2.05 | -$1.24 | -$2.03 | -63.71% | $36.31M | $77.04M | $99.39M | 29.02% | Get Alert |
02/11/2021 | PM | RARE | Q4 | -$1.62 | -$1.16 | -$0.37 | 68.10% | $35.59M | $70.54M | $91.54M | 29.77% | Get Alert |
10/27/2020 | PM | RARE | Q3 | -$1.96 | -$1.27 | -$1.13 | 11.02% | $25.80M | $53.89M | $81.47M | 51.18% | Get Alert |
07/30/2020 | PM | RARE | Q2 | -$1.72 | -$1.54 | -$1.12 | 27.27% | $24.15M | $39.12M | $61.71M | 57.74% | Get Alert |
05/06/2020 | PM | RARE | Q1 | -$1.82 | -$1.69 | -$2.05 | -21.30% | $18.17M | $36.58M | $36.31M | -0.74% | Get Alert |
02/13/2020 | PM | RARE | Q4 | -$1.73 | -$1.65 | -$1.62 | 1.82% | $16.26M | $32.15M | $35.59M | 10.71% | Get Alert |
11/05/2019 | PM | RARE | Q3 | -$1.74 | -$1.68 | -$1.96 | -16.67% | $11.76M | $28.94M | $25.80M | -10.85% | Get Alert |
Ultragenyx Pharmaceutical (RARE) is scheduled to report earnings on May 6, 2024. The last reported earnings were for reported on February 15, 2024 for Q4.
The Actual EPS was $-1.52, which beat the estimate of $-1.62.
The Actual Revenue was $127.4M, which beat the estimate of $119.4M.
Browse earnings estimates, EPS, and revenue on all stocks.